RCM
CRXTW

Rivernorth Capital Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Rivernorth Capital Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-66,986
Closed -$19K – 898
2021
Q4 		$19K Hold
66,986
– – ﹤0.01% 665
2021
Q3 		$50K Sell
66,986
-58,014
-46% -$43.7K ﹤0.01% 451
2021
Q2 		$94K Hold
125,000
– – 0.01% 408
2021
Q1 		$69K Buy
+125,000
New +$100K ﹤0.01% 388

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $455M AUM 2.3% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Rivernorth Capital Management's CRXTW Position: Q1 2022 in Review

Rivernorth Capital Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q1 2022, closing a stake of 66,986 shares — an estimated $19K sold.

Rivernorth Capital Management first reported a position in CRXTW in Q1 2021 and held it in 4 quarters. The position peaked at $94K in Q2 2021. 16 funds tracked by Wall St. Rank hold CRXTW as of Q1 2022.

  • Rivernorth Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q1 2022 after selling out during the quarter.
  • Rivernorth Capital Management sold 66,986 Clarus Therapeutics Holdings, Inc. Warrants shares in Q1 2022, an estimated $19K.
  • Rivernorth Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q1 2021 and held it in 4 quarters.
  • Rivernorth Capital Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $94K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q1 2022.

Based on Rivernorth Capital Management's 13F filing for Q1 2022, filed 16 May 2022.